The ANCHOR-CRC study (ClinicalTrials.gov identifier: NCT03693170) has introduced targeted-drug triple therapy as a first-line treatment for patients with mCRC with BRAF V600E mutations. Here, BRAF is linked to colorectal carcinoma.